Transgender Hormone Treatment Safe

Cross-sex hormone treatment of transgender adults leads to very few long-term side effects, according to the authors of the largest study to date to examine this issue.
“when using the guidelines from the Endocrine Society [“Endocrine Treatment of Transsexual Persons”], you are not going to see a lot of comorbidities with cross-sex hormone treatment.”

At entry into the study (baseline), the most common comorbidity in both groups was depression, with a 24.9% incidence in MTF subjects and 13.6% in FTM. Even after treatment, 26 (2.4%) of the MTF subjects and 7 (1.4%) of the FTM subjects still reported depression, leading Dr. Asscheman to tell the large audience, “Sex-reassignment treatment does not cure depression.”

Another comorbidity before transgender hormonal therapy is hypothyroidism. Hypothyroidism is also associated with depression.

Please treat your depression as another part of your health.

Leave a Reply

Your email address will not be published. Required fields are marked *